SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications
SGLT2抑制剂或二甲双胍作为早期2型糖尿病的标准治疗方案?SMARTEST研究的基线数据,这是一项新型的、分散式的、基于注册数据的随机试验,旨在预防糖尿病并发症。
期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.70320
Eriksson, Jan W; Fanni, Giovanni; Lundqvist, Martin H; Jansson, Stefan; Rådholm, Karin; Sofizadeh, Sheyda; Patsoukaki, Vagia; Nilsson, Albert; Lindholm, Daniel; Rolandsson, Olov; Norhammar, Anna; Granstam, Elisabet; Eliasson, Björn; Bennet, Louise; Sundström, Johan